

ABSTRACT OF THE DISCLOSURE

This invention discloses methods, kits, and instructions to treat neovascu-
lature diseases of the eye through the administration of a targeted photosensitizing agent
and subsequent exposure to light of specific wavelength sufficient to photoactivate
photosensitizing agent. The photosensitizing agent is bound to a composition that
mediates site specific delivery to a neovascu-
lature target tissue of a therapeutically
effective amount of a photosensitizing agent that is activated by a relatively low
fluence rate of light over a prolonged period of time. Diseases treatable under this
invention, include: diabetic retinopathy; macular degeneration; and malignant uveal
melanomas.